Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 26, 2025

Nvidia makes a deal with Groq, investing resolutions for 2026

View original at finance.yahoo.com
Nvidia makes a deal with Groq, investing resolutions for 2026 On Morning Brief, Yahoo Finance Executive Editor Brian Sozzi breaks down the biggest developing market stories on December 26, 2025…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • China's going to reopen for Nvidia, which wasn't necessarily fully factored in

    80% confidence
  • Jonathan Ross is no joke

    80% confidence
  • The biggest concern for 2026 markets is uncertainty from tariffs and midterm elections

    80% confidence
  • Tesla bull case is 3 trillion, base case is 2 trillion market cap

    80% confidence
  • Alex Karp is playing chess as a master wizard while others are playing checkers at the kids' table

    80% confidence
  • Tesla's robotics initiatives are conservatively worth a trillion dollars

    80% confidence
  • Stocks have enjoyed a Santa Claus rally in nearly 80% of the last 50 years

    80% confidence
  • For the first time in 30 years, the US is ahead of China when it comes to tech

    80% confidence
  • Adobe is probably under the most pressure given AI impact on their business model

    80% confidence
  • Enterprise AI adoption acceleration has been the biggest surprise, with capex 50% higher than beginning of year

    80% confidence
  • 2026 is going to be probably the most important year in Tesla's history

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com